Leading medical journals propose mandate on clinical data sharing

The International Committee of Medical Journal Editors (ICMJE) proposes new rules that will require authors to share clinical trial data as a prerequisite for their manuscripts to be considered for publication. The goal is to improve the benefit to society from the efforts of patients who volunteer to participate in clinical trials. The ICMJE proposal is outlined in an editorial published simultaneously today in Annals of Internal Medicine and 13 other ICMJE member journals.

"Enabling responsible data sharing is a major endeavor that will affect the fabric of how clinical trials are planned and conducted and how their data are used," writes lead author Darren Taichman, MD, PhD, Secretary, ICMJE and Executive Deputy Editor of Annals of Internal Medicine. "By changing the requirements of the manuscripts we will consider for publication in our journals, editors can help foster this endeavor."

The ICMJE defines a clinical trial as any research project that prospectively assigns people or a group of people to an intervention to study the cause-and-effect relationship between a health-related intervention and a health outcome. The ICMJE believes there is an ethical obligation to share data generated by interventional clinical trials because participants put themselves at risk. They say that sharing data should increase confidence and trust in the conclusions drawn from clinical trials, enable independent confirmation of results, and foster the development and testing of new hypotheses. If done well, data sharing will benefit patients, investigators, sponsors, and society.

The ICMJE is seeking and will consider feedback before it adopts new data sharing requirements. Comments are welcome at http://www.icmje.org/ and should be received by April 2016. It anticipates that new data-sharing requirement will go into effect for clinical trials that begin to enroll participants beginning 1 year after the ICMJE adopts the new policy.

About the International Committee of Medical Journal Editors
The ICMJE is a small working group of general medical journal editors whose participants meet annually and fund their own work on the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals.

About Annals of Internal Medicine
Annals of Internal Medicine is one of the most widely cited and influential medical journals in the world, with an impact factor of 17.810 - the highest of any specialty journal in its category. Annals' mission is to promote excellence in medicine, enable physicians and other health care professionals to be well informed members of the medical community and society, advance standards in the conduct and reporting of medical research, and contribute to improving the health of people worldwide. Established in 1927, Annals is the flagship journal of the American College of Physicians (ACP).

Most Popular Now

Novartis drug Zykadia receives FDA Priority Review…

Novartis today announced that the US Food and Drug Administration (FDA) accepted the Company's supplemental New Drug Application (sNDA) for filing, and granted Priority R...

Read more

Mutual Recognition promises new framework for phar…

The United States and the European Union (EU) completed an exchange of letters to amend the Pharmaceutical Annex to the 1998 U.S.-EU Mutual Recognition Agreement. Under t...

Read more

New analysis shows Novartis Entresto improves glyc…

Novartis has announced results of a new post-hoc analysis in a subgroup of patients with reduced ejection fraction heart failure (HFrEF) and diabetes suggesting that Entr...

Read more

Drugs similar to aspirin, ibuprofen could help tre…

A potentially life-saving treatment for sepsis has been under our noses for decades in the non-steroidal anti-inflammatory drugs (NSAIDs) most people have in their medici...

Read more

Novartis' Cosentyx shows almost all psoriasis pati…

Novartis has announced a new analysis showing that moderate-to-severe psoriasis patients treated with Cosentyx® (secukinumab) rapidly regain clear or almost clear skin (P...

Read more

Scientists stimulate immune system, stop cancer gr…

Researchers at the University of Illinois at Chicago report that increasing expression of a chemical cytokine called LIGHT in mice with colon cancer activated the immune ...

Read more

Potential drug candidates halt prostate and breast…

Scientists on the Florida campus of The Scripps Research Institute (TSRI) have designed two new drug candidates to target prostate and triple negative breast cancers. The...

Read more

Johnson & Johnson completes acquisition of Abb…

Johnson & Johnson (NYSE: JNJ) has completed the acquisition of Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott. The all-cash $4.325 billion acquisition w...

Read more

New England Journal of Medicine publishes long-ter…

In 2001 the U.S. Food and Drug Administration granted priority review for imatinib mesylate, sold under the name Gleevec®*, as an oral therapy for patients with chronic m...

Read more

Bristol-Myers Squibb expands focus on precision me…

Bristol-Myers Squibb Company (NYSE: BMY) announced its equity investment and plans for a research collaboration with GRAIL Inc., a life sciences company whose mission is ...

Read more

Volkswagen's excess emissions will lead to 1,200 p…

In September 2015, the German Volkswagen Group, the world's largest car producer, admitted to having installed "defeat devices" in 11 million diesel cars sold worldwide b...

Read more

Another record year for Bayer - good progress with…

Bayer had a very successful year in 2016, both strategically and operationally. Sales of the Bayer Group increased in 2016 by 1.5 percent (Fx & portfolio adj. 3.5 percent...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]